pulmonary embolism

systematic review meta-analysis network meta-analysis

Select antithromboticsfibrinolysis All type of patient       anticoagulantdirect anti-Xafibrinolyticlow molecular weight heparinoutpatient treatmentreversible longlasting indirect inhibitor of activated factor Xsynthetic oligosaccharide candesartanapixabanCertoparindalteparinenoxaparinfondaparinuxidraparinuxnadroparinreviparinrivaroxabanrt-PAstreptokinasetenecteplasetinzaparinurokinase vs anticoagulantvs discontinuationvs no anticoagulantvs heparin/VKAvs inpatient treatmentvs unfractioned heparin       DOAC without heparin

Filter

Group by Group by... nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition MA  in first nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in second nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in third	Description Synopsis Comparison Treatments Patients Characteristics Method Risk of bias References None Tools Indexation					Results Global trial result Main results All results All result tag NCT results	Major bleeding (15)symptomatic venous thromboembolism at the end of treatment (14)All cause death (14)Minor bleeding (6)VTE (5)recurrence of pulmonary embolism (5)fatal pulmonary embolism (4)non-fatal pulmonary embolism (3)major or clinically relevant non-major bleeding (2)recurrent symptomatic venous thromboembolism and death at the end of treatment (1)recurrent VTE during treatment (1)Symptomatic deep-vein thrombosis (1)symptomatic pulmonary embolism (1)Death related to venous thromboembolism (1) Options Numeric bar chart forest plot medians
Trial	Studied trt	Control trt	patients	tags	ROB	Trial result	Major bleeding	symptomatic venous thromboembolism at the end of treatment
antithrombotics
not classified
BARRIT, 1960	anticoagulant	no anticoagulant				suggesting
CASSIOPEA, 2012      NCT	idrabiotaparinux	warfarin			Low risk of bias	negative
Otero, 2010      NCT	outpatient treatment	inpatient treatment			Risk of bias	negative
OTPE (Aujesky), 2011      NCT	outpatient treatment	inpatient treatment			Risk of bias	negative
apixaban
AMPLIFY-EXT 2.5mg, 2012      NCT	apixaban 2.5mg	discontinuation			Low risk of bias	suggesting
AMPLIFY-EXT 5mg, 2012      NCT	apixaban 5mg	discontinuation			Low risk of bias	suggesting
AMPLIFY, 2013      NCT	apixaban (without LMWH)	LMWH/VKA		DOAC without heparin	Low risk of bias	suggesting
Certoparin
Certoparin-Study Group sub group, 1998	Certoparin	unfractionated heparin			Exploratory	negative
dalteparin
Kuijer, 1995	Dalteparin	unfractionated heparin				negative
Meyer, 1995	Dalteparin	unfractionated heparin				negative
enoxaparin
PREPIC, 1998	Enoxaparin	unfractionated heparin			Risk of bias	negative
Merli sub group, 2001	Enoxaparin	unfractionated heparin			Exploratory	negative
fondaparinux
MATISSE PE, 2003	fondaparinux	heparin			Risk of bias	negative
idraparinux
VanGogh PE, 2007    NCT	idraparinux (without heparin)	heparin/VKA			Risk of bias	negative
nadroparin
European multicentre study, 1991	Nadroparin	unfractionated heparin			Risk of bias	negative
Prandoni sub-group, 1992	Nadroparin	unfractionated heparin			Exploratory	negative
Thery, 1992	Nadroparin	unfractionated heparin			Exploratory	negative
reviparin
COLOMBUS sub group, 1997	Reviparin	unfractionated heparin			Exploratory	negative
rivaroxaban
Einstein-PE Evaluation, 2012      NCT	rivaroxaban (without LMWH)	LMWH/VKA			Risk of bias	-
tinzaparin
ACTSG (Hull) sub-group, 1992	Tinzaparin	unfractionated heparin			Low risk of bias	negative
Campbell, 1998	Tinzaparin	unfractionated heparin				negative
THESEE, 1997	Tinzaparin	unfractionated heparin			Risk of bias	negative
fibrinolysis
not classified
MOPETT, 2012	half-dose t-PA	no fibrinolysis				-
candesartan
Tebbe, 2009	desmoteplase	alteplase			Exploratory	-
rt-PA
PAIMS 2, 1992	rt-PA	no fibrinolysis			Exploratory	negative
Goldhaber, 1993	rt-PA	no fibrinolysis			Exploratory	negative
PIOPED, 1990	rt-PA	placebo			Low risk of bias	negative
Levine, 1990	rt-PA	placebo			Low risk of bias	negative
Konstantinides, 2002	rt-PA	placebo			Low risk of bias	negative
streptokinase
Tibbutt, 1974	streptokinase	no fibrinolysis			Exploratory	negative
Ly, 1978	streptokinase	no fibrinolysis			Exploratory	negative
Jerjes-Sanchez, 1995	streptokinase	no fibrinolysis			Exploratory	-
urokinase
Marini, 1988	urokinase	no fibrinolysis			Exploratory	-
UPET, 1973	urokinase	placebo			Low risk of bias	negative